Cynthia A. Harris

Cynthia A. Harris

Auto-generated profile, based on publicly available information

Cynthia A. Harris

Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NCNimrat Chatterjee
Nimrat Chatterjee
MWMatthew A. Whitman
Matthew A. Whitman
CHCynthia A. Harris
Cynthia A. Harris
SMSophia M. Min
Sophia M. Min
OJOliver Jonas
Oliver Jonas
GWGraham C. Walker
Graham C. Walker
Significance: Mutagenic translesion synthesis (TLS) increases cell survival after DNA damage by bypassing lesions that normally block DNA replication but introduces mutations. In cancer cells, REV1/POLζ-dependent mutagenic TLS can contribute to intrinsic chemoresistance, while the mutations it introduces can underlie acquired chemoresistance. Interfering with this TLS pathway genetically or with the small molecule inhibitor JH-RE-06 has been shown to improve cisplatin chemotherapy by suppressing tumor growth and enhancing survival in mouse xenograft tumor models. Cisplatin chemotherapy commonly exerts its antitumor effects via DNA damage-mediated apoptosis. However, in two mouse xenograft models and four mammalian cell lines, the JH-RE-06 unexpectedly profoundly alters the biological response to cisplatin. Apoptosis is suppressed and surprisingly numerous hallmarks of senescence are induced prior to cell death.

13 March 2026 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
KDKirandeep K. Deol
Kirandeep K. Deol
CHCynthia A. Harris
Cynthia A. Harris
STSydney J. Tomlinson
Sydney J. Tomlinson
CDColin J. Delaney
Colin J. Delaney
AAAmr Al-Farhan
Amr Al-Farhan
JOJames A. Olzmann
James A. Olzmann
Ferroptosis, a regulated form of cell death driven by excessive lipid peroxidation, has emerged as a promising therapeutic target in cancer. Ferroptosis suppressor protein 1 (FSP1) is a critical regulator of ferroptosis resistance, yet the mechanisms controlling its expression and stability remain mostly unexplored. To uncover regulators of FSP1 abundance, we conducted CRISPR–Cas9 screens using a genome-edited, dual-fluorescent FSP1 reporter cell line, identifying both transcriptional and post-translational mechanisms that determine FSP1 levels. Notably, we identified riboflavin kinase and flavin adenine dinucleotide (FAD) synthase, enzymes that are essential for synthesizing FAD from vitamin B2, as key contributors to FSP1 stability. Biochemical and cellular analyses revealed that FAD binding is critical for both FSP1 activity and stability. FAD deficiency and mutations blocking FSP1–FAD binding triggered FSP1 degradation through a ubiquitin–proteasome pathway involving the E3 ligase RNF8. Unlike other vitamins that inhibit ferroptosis by scavenging radicals, vitamin B2 supports ferroptosis resistance through FAD cofactor binding, ensuring proper FSP1 stability and function. This study provides a rich resource detailing mechanisms that regulate FSP1 abundance and highlights a novel connection between vitamin B2 metabolism and ferroptosis resistance, with implications for therapeutic strategies targeting FSP1 in cancer.

12 December 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CHCynthia A. Harris
Cynthia A. Harris
JOJames A. Olzmann
James A. Olzmann